Clinical-stage drug development company Syntara (ASX:SNT), formerly Pharmaxis, has commenced dosing in the final cohort of a phase 2 clinical trial studying its pan-LOX inhibitor SNT-5505 in patients with myelofibrosis. …
Syntara commences dosing in phase 2 myelofibrosis trial of its pan-LOX inhibitor
December 13, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News